Skip to content
NBRDA and Basani sign Memorandum of Agreement to advance genomics, digital health and biotechnology innovation in Nigeria
Basani

Genomics Data Infrastructure

Population-scale genomic data is the hardest thing an institution can be asked to hold. We build the consent, registry, custody and access systems around it.

In short

Consent, registry, custody and access systems for population-scale genomic programmes, built to international standards.

Scope

What It Covers

Consent systems

Consent capture designed for multilingual and low-literacy contexts, versioning, and withdrawal that propagates downstream.

Participant registries

Identity resolution and deduplication at national scale, without making participants re-identifiable to analysts.

Sample accessioning

Barcoding and chain of custody tracking from collection point to sequencer.

Controlled access

Analysis in place with no raw data egress, data access committee workflow, and query-level audit.

Method

How We Approach It

We build to the published standards of the Global Alliance for Genomics and Health, so a national resource can be queried by international collaborators without the data leaving the country.

Residency is enforced in the architecture rather than promised in a contract. Federated query means the transfer never has to happen.

We operate infrastructure. We do not own the data or hold the specimens, and the systems are built so that ownership stays where the law puts it.

Precedent

Nigeria Nearly Lost 130,000 Genomes

A Nigerian genomics company spent four years building a biorepository of samples and clinical data from around 130,000 West African participants. Its holding company was registered in the United States. Its biobank was in Nigeria.

When the company failed, control sat with the offshore entity. By late 2023 the repository was being shopped to buyers. Reporting on the dispute put the biodata of 100,000 Nigerians on offer at three million dollars, against a company once valued at a hundred and seventy million. In 2025 the Federal High Court in Lagos granted an injunction halting the sale.

The injunction held. But it was a court order obtained late, in litigation the participants were never party to. The infrastructure that would have made it unnecessary did not exist. That is what this service line is for.

130,000+
unique patient samples held in the biobank. Company statement, 2022
$3M
reported asking price for the biodata of 100,000 Nigerians. TechCabal, 2025
$170M
the company's peak valuation. Reported, Series B

Contact

Talk to Us

Tell us what you are planning and we will tell you honestly whether we are the right people to build it.